161 related articles for article (PubMed ID: 38049320)
1. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
[No Abstract] [Full Text] [Related]
2. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
3. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
Shao S; Liu HX; Jiang Y; Li S; Wei DL; Zhu J; Wang C; Zhao CX
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):115-120. PubMed ID: 38604786
[No Abstract] [Full Text] [Related]
4. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
[No Abstract] [Full Text] [Related]
5. [Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation].
Li XH; Gao CJ; DA WM; Cao YB; Xu LX; Wu YM; Liu B; Liu ZY; Yan B; Li SW; Yang XL; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1535-40. PubMed ID: 24370044
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
[TBL] [Abstract][Full Text] [Related]
8. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
12. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
13. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.
Verbeek AB; Jansen SA; von Asmuth EGJ; Lankester AC; Bresters D; Bierings M; Mohseny AB; Lindemans CA; Buddingh EP
Transplant Cell Ther; 2022 Sep; 28(9):600.e1-600.e9. PubMed ID: 35717003
[TBL] [Abstract][Full Text] [Related]
16. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
17. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
19. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
